Search

Your search keyword '"A. M. Gasco"' showing total 65 results

Search Constraints

Start Over You searched for: Author "A. M. Gasco" Remove constraint Author: "A. M. Gasco"
65 results on '"A. M. Gasco"'

Search Results

2. N-substituted analogues of S-nitroso-<scp> N </scp> -acetyl-<scp>D</scp> ,<scp>L</scp> -penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries

3. [Untitled]

4. New 1,4-Dihydropyridines Conjugated to Furoxanyl Moieties, Endowed with Both Nitric Oxide-like and Calcium Channel Antagonist Vasodilator Activities

5. Glutathione potentiates cGNP synthesis induced by the two phenylfuroxancarbonitrile isomers in RFL-6 cells

6. The Furoxan System as a Useful Tool for Balancing 'Hybrids' with Mixed .alpha.1-Antagonist and NO-like Vasodilator Activities

7. Effect of red maca (Lepidium meyenii) on prostate zinc levels in rats with testosterone-induced prostatic hyperplasia

8. Evaluation of different doses of mashua (Tropaeolum tuberosum) on the reduction of sperm production, motility and morphology in adult male rats

9. Serum testosterone levels and score of chronic mountain sickness in Peruvian men natives at 4340 m

10. Effect of the ethanolic extract from Fagara tessmannii on testicular function, sex reproductive organs and hormone level in adult male rats

11. No-Mimetic Furoxans: Arylsulphonylfuroxans and Related Compounds

12. Unsymmetrically Substituted Furoxans, XIV. Synthesis and Structure of a Trimer of the Furoxan System with High Vasodilator and Platelet Antiaggregatory Activity

15. ChemInform Abstract: Use of Nitric Oxide Releasing Furoxan System in the Design of 'Hybrids' : Substitution of Furoxan Moieties for the Furan Ring in Prazosin

24. Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan

25. New potential uroselective NO-donor alpha1-antagonists

26. Imatinib Mesylate in Desmoplastic Small Round Cell Tumour

27. [Guidelines for basic and advanced cardiopulmonary resuscitation of children. Commission for Cardiopulmonary Resuscitation of the Spanish Society for Anesthesiology and Resuscitation]

28. Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit?

29. Unsymmetrically substituted furoxans, XIII. Phenylfuroxancarbaldehydes and related compounds

30. Characterisation of furoxancarbonitriles as a new class of vasodilators

31. Vinorelbine as palliative therapy in advanced breast cancer

32. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer

33. Mitoxantrone in elderly women with advanced breast cancer: a phase II study

34. The cyano-NNO-azoxy function in the design of an irreversible label for alpha 1 adrenoreceptors

35. Superiority of Choi vs Recist Criteria in Evaluating Outcome of Advanced Soft Tissue Sarcoma (STS) Patients Treated with Sorafenib

36. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation

37. THE REDUCTION OF BENZOFUROXANS BY FERROUS SALTS AND BY THIOPHENOL

38. [Study of Navarra (PECNA). Correlation of arterial blood pressure, in a child-young population, with anthropometric and biochemical parameters]

39. [The Navarra study. Prevalence of arterial hypertension, hyperlipidemia and obesity in the infant-child population of Navarra. Association of risk factors]

40. [A study from Navarra. Hyperlipidemia V. What is the best definition of hyperlipemia in childhood and adolescence?]

41. [A study from Navarra. Hyperlipidemias. Avarage scores and percentiles for lipids and lipoproteins in a population of children and adolescents. Correlation with anthropometric parameters]

42. [The Navarra study (PECNA). Hyperlipidemia IV. Prevalence of hyperlipidemia in the infant- and juvenile population of Navarra. Variations based on age, gender and health care accessibility]

43. [The Navarra study (PECNA). Hyperlipidemia III. Variations in the median HDL levels and lipid risk quotient in children and adolescents based on age and gender]

44. Pharmacochemistry of the furoxan ring: recent developments

45. [Study from Navarra. Variations in the average arterial blood pressure level according to age, gender and body height]

46. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells

47. Synthesis and H2-antagonist properties of some 1,2,5-thiadiazole-1-oxide derivatives

48. Synthesis and cardiovascular properties of furazanyl-1,4-dihydropyridines and of furoxanyl analogues

49. Novel genes mediating cisplatin resistance in head and neck cancer

50. [Significance of cholesterol as a risk factor in children and adolescents]

Catalog

Books, media, physical & digital resources